Valérie Vingtdeux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9360053/publications.pdf

Version: 2024-02-01

50 papers

4,737 citations

172207 29 h-index 50 g-index

60 all docs

60 docs citations

60 times ranked

9089 citing authors

#	Article	IF	Citations
1	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. Journal of Biomedical Science, 2019, 26, 89.	2.6	20
2	Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process. Cell Death and Disease, 2019, 10, 221.	2.7	54
3	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiology of Disease, 2019, 129, 217-233.	2.1	21
4	Study of AMPK-Regulated Metabolic Fluxes in Neurons Using the Seahorse XFe Analyzer. Methods in Molecular Biology, 2018, 1732, 289-305.	0.4	7
5	AMP-activated Protein Kinase Controls Immediate Early Genes Expression Following Synaptic Activation Through the PKA/CREB Pathway. International Journal of Molecular Sciences, 2018, 19, 3716.	1.8	29
6	Contribution of the Endosomal-Lysosomal and Proteasomal Systems in Amyloid-Î ² Precursor Protein Derived Fragments Processing. Frontiers in Cellular Neuroscience, 2018, 12, 435.	1.8	24
7	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect \hat{l}^2 -secretase inhibitors. European Journal of Medicinal Chemistry, 2018, 159, 104-125.	2.6	16
8	AMP-Activated Protein Kinase Is Essential for the Maintenance of Energy Levels during Synaptic Activation. IScience, 2018, 9, 1-13.	1.9	59
9	A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate AÎ ² Peptides. Molecular Medicine, 2016, 22, 841-849.	1.9	7
10	CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. Scientific Reports, 2016, 6, 24250.	1.6	30
11	AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Scientific Reports, 2016, 6, 26758.	1.6	95
12	AMPK in Neurodegenerative Diseases. Exs, 2016, 107, 153-177.	1.4	38
13	AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives. Current Drug Targets, 2016, 17, 890-907.	1.0	31
14	Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism. ACS Chemical Neuroscience, 2015, 6, 559-569.	1.7	35
15	CALHM1 ion channel elicits amyloid- \hat{l}^2 clearance by insulin-degrading enzyme in cell lines and <i>in vivo</i> in the mouse brain. Journal of Cell Science, 2015, 128, 2330-2338.	1.2	32
16	Postnatal neurodevelopmental expression and glutamate-dependent regulation of the ZNF804A rodent homologue. Schizophrenia Research, 2015, 168, 402-410.	1.1	12
17	Effect of the CALHM1 G330D and R154H Human Variants on the Control of Cytosolic Ca2+ and $\hat{Al^2}$ Levels. PLoS ONE, 2014, 9, e112484.	1.1	11
18	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. Molecular Medicine, 2014, 20, 29-36.	1.9	55

#	Article	IF	Citations
19	Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid \hat{l}^2 . Journal of Neuroscience, 2014, 34, 12230-12238.	1.7	143
20	Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke. Proteome Science, 2014, 12, 24.	0.7	17
21	CALHM1 controls the Ca2+-dependent MEK, ERK, RSK and MSK signaling cascade in neurons. Journal of Cell Science, 2013, 126, 1199-1206.	1.2	35
22	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging, 2013, 34, 757-769.	1.5	16
23	CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature, 2013, 495, 223-226.	13.7	405
24	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. Molecular Medicine, 2013, 19, 29-36.	1.9	22
25	Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimer's Disease. Frontiers in Physiology, 2012, 3, 229.	1.3	93
26	Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca $\langle \sup 2+\langle \sup \rangle$ regulation of neuronal excitability. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1963-71.	3.3	132
27	Identification of potent smallâ€molecule inhibitors of <scp>STAT</scp> 3 with antiâ€inflammatory properties in <scp>RAW</scp> Â264.7 macrophages. FEBS Journal, 2012, 279, 3791-3799.	2.2	29
28	Gas1 Interferes with ${\rm A\hat{I}^2PP}$ Trafficking by Facilitating the Accumulation of Immature ${\rm A\hat{I}^2PP}$ in Endoplasmic Reticulum-Associated Raft Subdomains. Journal of Alzheimer's Disease, 2012, 28, 127-135.	1.2	2
29	Identification and biology of αâ€secretase. Journal of Neurochemistry, 2012, 120, 34-45.	2.1	77
30	Resveratrol mitigates lipopolysaccharide―and Aβâ€mediated microglial inflammation by inhibiting the TLR4/NFâ€₽B/STAT signaling cascade. Journal of Neurochemistry, 2012, 120, 461-472.	2.1	363
31	CALHM1 P86L Polymorphism Modulates CSF Aβ Levels in Cognitively Healthy Individuals at Risk for Alzheimer's Disease. Molecular Medicine, 2011, 17, 974-979.	1.9	26
32	Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and RSVA405, Inhibit Adipogenesis. Molecular Medicine, 2011, 17, 1022-1030.	1.9	75
33	Contribution of Multivesicular Bodies to the Prion-Like Propagation of Lesions in Alzheimer's Disease. , 2011, , .		0
34	AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathologica, 2011, 121, 337-349.	3.9	247
35	Novel synthetic smallâ€molecule activators of AMPK as enhancers of autophagy and amyloidâ€Î² peptide degradation. FASEB Journal, 2011, 25, 219-231.	0.2	209
36	Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid- \hat{l}^2 precursor protein. Human Molecular Genetics, 2011, 20, 2026-2036.	1.4	15

#	Article	IF	CITATIONS
37	AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-Î ² Peptide Metabolism. Journal of Biological Chemistry, 2010, 285, 9100-9113.	1.6	560
38	Letter to the Editor on "Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesisâ€. Biochemical and Biophysical Research Communications, 2010, 400, 452.	1.0	1
39	Down-Regulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane Proteolysis. Molecular Biology of the Cell, 2009, 20, 2495-2507.	0.9	92
40	Epstein-Barr Virus Protein EB2 Contains an N-Terminal Transferable Nuclear Export Signal That Promotes Nucleocytoplasmic Export by Directly Binding TAP/NXF1. Journal of Virology, 2009, 83, 12759-12768.	1.5	31
41	Calcium signaling in neurodegeneration. Molecular Neurodegeneration, 2009, 4, 20.	4.4	258
42	Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats. Experimental Neurology, 2008, 210, 467-478.	2.0	47
43	A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Aβ Levels, and Alzheimer's Disease Risk. Cell, 2008, 133, 1149-1161.	13.5	310
44	Response: CALHM1 Association with Alzheimer's Disease Risk. Cell, 2008, 135, 994-996.	13.5	25
45	Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neuroscience, 2008, 9, S6.	0.8	178
46	Alkalizing Drugs Induce Accumulation of Amyloid Precursor Protein By-products in Luminal Vesicles of Multivesicular Bodies. Journal of Biological Chemistry, 2007, 282, 18197-18205.	1.6	176
47	Protein Kinase CK2 Phosphorylation of EB2 Regulates Its Function in the Production of Epstein-Barr Virus Infectious Viral Particles. Journal of Virology, 2007, 81, 11850-11860.	1.5	30
48	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiology of Disease, 2007, 25, 686-696.	2.1	78
49	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiology of Disease, 2005, 20, 625-637.	2.1	82
50	Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A \hat{l}^2 42 Accumulation in a Novel Alzheimer Transgenic Model. American Journal of Pathology, 2004, 165, 1289-1300.	1.9	375